2020
Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Usmani S, Facon T, Moreau P, Dimopoulos M, Mateos M, Costa L. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. Journal Of Clinical Oncology 2020, 38: 8540-8540. DOI: 10.1200/jco.2020.38.15_suppl.8540.Peer-Reviewed Original ResearchHigh-risk cytogeneticsProgression-free survivalPhase III trialsMultiple myelomaR settingIII trialsMature overall survival dataDerSimonian-Laird random-effects modelPhase III randomized trialsRandomized phase III trialFirst-line settingOverall survival dataImproved response ratesRandom-effects modelLog hazard ratioBackbone regimenBackbone regimensHRC patientsRefractory settingPrimary endpointSame regimenFree survivalCytogenetic riskMM patientsRandomized trials
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens